Cabometyx

DRUG2 trials

Sponsors

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Asan Medical Center

Conditions

Metastatic Renal Cell CarcinomaRenal Cell Cancer

Phase 2

A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma

CompletedNCT03463681

Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoMetastatic Renal Cell Carcinoma

Start: 2018-06-11End: 2021-04-08Updated: 2021-04-26

Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma

Asan Medical CenterRenal Cell Cancer

Start: 2021-03-01End: 2025-02-28Target: 201Updated: 2021-01-19

Related Papers

Cabozantinib as subsequent therapy to an immune checkpoint-based therapy in renal cell carcinoma, phase 2 interventional study (AT ASIA, KCSG GU21-02).

Journal of Clinical Oncology2025-02-10

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

Tumori Journal2022-11-2946 citations

A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681).

Journal of Clinical Oncology2021-05-208 citations

A phase II open-label study of cabozantinib after first-line treatment including an immune-checkpoint combination in patients with advanced or unresectable renal cell carcinoma: The BREAKPOINT trial (MeetUro trial 03 - EudraCT number 2018-000582-36).

Journal of Clinical Oncology2021-02-209 citations

A phase II open-label study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune-checkpoint inhibitor: The BREAKPOINT trial.

Journal of Clinical Oncology2019-03-012 citations